trending Market Intelligence /marketintelligence/en/news-insights/trending/77qZNqNfkeYVqWKy5Do3LA2 content esgSubNav
In This List

Master Pharm Q2 profit falls YOY

Case Study

Powering the markets of the future with data and AI

Case Study

An Alternative Investment Team Harnesses Textual Data Analytics to Find New Sources of Alpha


Analyzing Sentiment in Quarterly Earnings Calls — Q3 2023


Battery metals - unbated long term need for supply security despite short-term headwinds

Master Pharm Q2 profit falls YOY

Master Pharm SA said its normalized net income for the second quarter amounted to 5 groszy per share, a decrease of 54.6% from 12 groszy per share in the year-earlier period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was 1.1 million zlotys, a decrease of 47.2% from 2.1 million zlotys in the prior-year period.

The normalized profit margin declined to 10.2% from 18.0% in the year-earlier period.

Total revenue declined 6.6% on an annual basis to 11.1 million zlotys from 11.8 million zlotys, and total operating expenses rose 11.2% year over year to 9.3 million zlotys from 8.4 million zlotys.

Reported net income fell 47.0% from the prior-year period to 1.4 million zlotys, or 6 groszy per share, from 2.6 million zlotys, or 14 groszy per share.

As of Aug. 17, US$1 was equivalent to 3.81 zlotys.